Determining the functions of LYVE1 on macrophages during autoantibody-induced valve disease

确定 LYVE1 在自身抗体诱导的瓣膜疾病期间对巨噬细胞的功能

基本信息

  • 批准号:
    10534827
  • 负责人:
  • 金额:
    $ 6.76万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-01 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Rheumatic diseases including rheumatoid arthritis, rheumatic heart disease, and systemic lupus erythematosus are associated with increased risk of cardiovascular disease. While inflammation is a critical link between rheumatic diseases and CVD, continued research is needed to determine causal mechanisms. The K/B.g7 model of spontaneous autoantibody-induced arthritis and mitral valve (MV) disease provides a valuable pre- clinical tool to elucidate disease-driving mechanisms related to valvular carditis, which is currently difficult to detect prior to the onset of reduced cardiac function. Prior work from our group demonstrated a role for macrophages in promoting valve disease. Single-cell sequencing data from inflamed MV reported a heterogeneous population of macrophages in this tissue prompting further inquiry into the macrophage subsets and subset-specific roles that drive disease. Preliminary data from our group demonstrated that lymphatic endothelial cells promote early stages of MV disease, but the mechanisms driving the growth of these neo- lymphatic structures remains unclear. We identified the presence of hyaluronan receptor LYVE1+ macrophages near the atrial layer of endothelium and MV LECs in both normal and diseased valves. Gene expression and flow cytometry profiling revealed that these cells are tissue resident macrophages. LYVE1+ macrophages have been identified in other locations in the heart as well as other tissues including the lung, adipose, and peritoneum. In these niches, LYVE1+ macrophages interact with tissue native hyaluronan, regulate extracellular matrix homeostasis, and promotes neovascular growth. Work proposed in this fellowship will test the hypothesis that a) early in disease, LYVE1+ macrophages promote MV disease at least in part by promoting lymphangiogenesis and b) the LYVE1 protein does not simply delineate this population of macrophages but is required for the macrophages to perform these functions. Using RNA sequencing, LYVE1+ and LYVE1- MV macrophage subsets will be compared to one another and across disease time points to identify the gene expression profile unique to LYVE1+ macrophages, which we predict will include lymphangiogenesis- and HA-binding-related transcripts. Beyond characterizing these cells, an inducible model of LYVE1+ macrophage depletion and LYVE1 WT and KO bone marrow chimeras will be used to test the necessity of this cell population and LYVE1 expression on macrophages, respectively, in driving both MV disease and lymphatic growth in diseased valves. Deep-tissue imaging and analysis techniques will be applied to further interrogate whether LYVE1+ macrophages preferentially interact with LECs to promote vessel growth. In all, these studies will elucidate important information about the role of innate immune responses in driving valvular carditis. These data can be used to improve our understanding of the early mechanisms driving human disease and potentially identify novel therapeutic targets or diagnostic markers.
项目总结/摘要 风湿性疾病包括类风湿性关节炎、风湿性心脏病和系统性红斑狼疮 与心血管疾病的风险增加有关。虽然炎症是 风湿性疾病和心血管疾病,需要继续研究,以确定因果机制。K/B.g7 自发性自身抗体诱导的关节炎和二尖瓣(MV)疾病的模型提供了一个有价值的预 阐明与瓣膜性心脏炎相关的疾病驱动机制的临床工具,目前很难 在心脏功能下降之前进行检测。我们小组以前的工作证明了 巨噬细胞促进瓣膜疾病。来自发炎MV的单细胞测序数据报告了 该组织中巨噬细胞的异质性群体促使进一步调查巨噬细胞亚群 和亚群特异性的作用。我们小组的初步数据表明, 内皮细胞促进MV疾病的早期阶段,但驱动这些新内皮细胞生长的机制, 淋巴结构仍不清楚。我们鉴定了透明质酸受体LYVE 1+巨噬细胞的存在, 在正常和病变瓣膜的内皮和MV LEC的心房层附近。基因表达和 流式细胞术分析显示这些细胞是组织驻留巨噬细胞。LYVE 1+巨噬细胞具有 在心脏的其他位置以及包括肺、脂肪和腹膜在内的其他组织中也发现了。 在这些小生境中,LYVE 1+巨噬细胞与组织天然透明质酸相互作用,调节细胞外基质 体内平衡,并促进新血管生长。本奖学金中提出的工作将检验以下假设: a)在疾病早期,LYVE 1+巨噬细胞至少部分地通过促进淋巴管生成来促进MV疾病 和B)LYVE 1蛋白并不简单地描绘该巨噬细胞群体,而是巨噬细胞的生长所需的。 巨噬细胞执行这些功能。使用RNA测序,LYVE 1+和LYVE 1- MV巨噬细胞 亚组将相互比较,并在疾病时间点之间进行比较,以确定基因表达谱 LYVE 1+巨噬细胞所特有的,我们预测这将包括淋巴管生成和HA结合相关的 成绩单除了表征这些细胞之外,LYVE 1+巨噬细胞消耗和LYVE 1+巨噬细胞消耗的诱导模型也可以用于研究。 WT和KO骨髓嵌合体将用于检测该细胞群和LYVE 1表达的必要性 在驱动MV疾病和病变瓣膜中的淋巴生长方面。深层组织 将应用成像和分析技术进一步询问LYVE 1+巨噬细胞是否 优先与LEC相互作用以促进血管生长。总之,这些研究将阐明 先天性免疫反应在驱动瓣膜性心脏炎中的作用。这些数据可以用于 提高我们对人类疾病早期驱动机制的理解,并可能发现新的 治疗靶点或诊断标志物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Victoria Osinski其他文献

Victoria Osinski的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 6.76万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.76万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 6.76万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.76万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 6.76万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.76万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 6.76万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 6.76万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 6.76万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.76万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了